Recombinant Mutant Human Tumor Necrosis Factor for Injection
[Dosage form] Freeze-dried powder for injection.
[Indication]
| in the treatment of non-small cell lung cancer (NSCLC ） | Combined therapy with NP chemotherapy (NVB+DDP） |
| Combined therapy with MVP chemotherapy vindesine+DDP+MMC） | |
| or in ineffective therapy for advanced or recurrent NSCLC patients with other methods | |
| in the treatment of non-Hodgkin's lymphoma （ NHL ） | Combined therapy with BACOP chemotherapy |
| (Cyclophosphamide +Vincristine +Doxorubicin ADM+Bleomycin +Prednisone ) | |
| or be used in trial by chemotherapy or other methods in the treatment of advanced NHL of invalid patients |
[Highlight]
•Promoting the concentration of chemotherapeutic drugs in tumor by 4 to 6 times
•Owning synergistic effect by combining various chemotherapeutics
•Promoting chemotherapeutic effect of advanced NSCLC and NHL significantly
•Effective rate is 87% in the treatment of Malignant pleural effusion applied as single drug
•Effective rate is 66.67% in the treatment of NHL applied as single drug
•The first recombinant mutant human tumor necrosis factor in the globe
